{
    "2018-11-30": [
        [
            {
                "time": "2018-11-30",
                "original_text": "收盘突破年线个股一览",
                "features": {
                    "keywords": [
                        "收盘",
                        "突破",
                        "年线",
                        "个股"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "金融"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-12-01",
                "original_text": "乐普医疗:氯吡格雷通过一致性评价,市场份额有望快速提升",
                "features": {
                    "keywords": [
                        "乐普医疗",
                        "氯吡格雷",
                        "一致性评价",
                        "市场份额",
                        "提升"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-12-02",
                "original_text": "【华泰医药代雯团队】乐普医疗 (300003.SZ, 买入) 事件点评：氯吡格雷通过一致性评价，有望受益带量采购",
                "features": {
                    "keywords": [
                        "华泰医药",
                        "乐普医疗",
                        "氯吡格雷",
                        "一致性评价",
                        "带量采购"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-12-03",
                "original_text": "乐普医疗（300003）重大事件快评：氯吡格雷通过一致性评价，抓住改革机遇抢占市场",
                "features": {
                    "keywords": [
                        "乐普医疗",
                        "氯吡格雷",
                        "一致性评价",
                        "改革",
                        "市场"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-12-04",
                "original_text": "乐普医疗：氯吡格雷通过一致性评价 望受益于带量采购试点",
                "features": {
                    "keywords": [
                        "乐普医疗",
                        "氯吡格雷",
                        "一致性评价",
                        "带量采购",
                        "试点"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-12-05",
                "original_text": "30股获券商买入评级 平高电气目标涨幅达52.09%",
                "features": {
                    "keywords": [
                        "券商",
                        "买入评级",
                        "平高电气",
                        "目标涨幅"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "电力设备"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-12-06",
                "original_text": "乐普医疗公告点评:氯吡格雷顺利通过一致性评价,静待政策利好",
                "features": {
                    "keywords": [
                        "乐普医疗",
                        "氯吡格雷",
                        "一致性评价",
                        "政策",
                        "利好"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}